The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Viral nanoparticles and virus‐like particles: platforms for contemporary vaccine design
Open accessAbstract
Current vaccines that provide protection against infectious diseases have primarily relied on attenuated or inactivated pathogens. Virus‐like particles (VLPs), comprised of capsid proteins that can initiate an immune response but do not include the genetic material required for replication, promote immunogenicity and have been developed and approved as vaccines in some cases. In addition, many of these VLPs can be used as molecular platforms for genetic fusion or chemical attachment of heterologous antigenic epitopes. This approach has been shown to provide protective immunity against the foreign epitopes in many cases. A variety of VLPs and virus‐based nanoparticles are being developed for use as vaccines and epitope platforms. These particles have the potential to increase efficacy of current vaccines as well as treat diseases for which no effective vaccines are available. WIREs Nanomed Nanobiotechnol 2011 3 174–196 DOI: 10.1002/wnan.119 This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Infectious Disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397
A vaccine against nicotine for smoking cessation: a randomized controlled trial
Cornuz, J., Zwahlen, S., Jungi, W. F., Osterwalder, J., Klingler, K., van Melle, G., Bangala, Y., Guessous, I., Müller, P., Willers, J., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002547 · Cited by 281
Maurer, P., Jennings, G. T., Willers, J., Rohner, F., Lindman, Y., Roubicek, K., Renner, W. A., Müller, P., & Bachmann, M. F. (2005) · European Journal of Immunology · doi:10.1002/eji.200526285 · Cited by 279 · cited 1×
“2, 66 MS2 is another well-characterized bacteriophage which has been utilized for attachment and display of viral epitopes.”
Bräutigam, S., Snezhkov, E., & Bishop, D. H. L. (1993) · Virology · doi:10.1006/viro.1993.1067 · Cited by 72
Cited by
COVID-19 vaccine development and a potential nanomaterial path forward
Shin, M. D., Shukla, S., Chung, Y. H., Beiss, V., Chan, S. K., Ortega-Rivera, O. A., Wirth, D. M., Chen, A., Sack, M., Pokorski, J. K., et al. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0737-y · Cited by 659
Bioengineering virus‐like particles as vaccines
Lua, L. H. L., Connors, N. K., Sainsbury, F., Chuan, Y. P., Wibowo, N., & Middelberg, A. P. J. (2014) · Biotechnology and Bioengineering · doi:10.1002/bit.25159 · Cited by 355
Application of built-in adjuvants for epitope-based vaccines
Lei, Y., Zhao, F., Shao, J., Li, Y., Li, S., Chang, H., & Zhang, Y. (2019) · PeerJ · doi:10.7717/peerj.6185 · Cited by 115
Universal label-free in-process quantification of influenza virus-like particles
Carvalho, S. B., Moleirinho, M. G., Wheatley, D., Welsh, J., Gantier, R., Alves, P. M., Peixoto, C., & Carrondo, M. J. T. (2017) · Biotechnology Journal · doi:10.1002/biot.201700031 · Cited by 30
Metadata
- Authors
- Plummer, E. M., & Manchester, M.
- Venue
- WIREs Nanomedicine and Nanobiotechnology
- Publisher
- Wiley
- Published
- 2010-09-24
- Volume
- 3
- Issue
- 2
- Pages
- 174-196
- ISSN
- 1939-0041 (ISSN-L)
- 1939-5116
- OpenAlex
- W2009126191
- Cited by
- 237
- References
- 4
- FWCI
- 8.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Viral nanoparticles and virus‐like particles: platforms for contemporary vaccine design. https://app.cochat.ai/papers/10.1002/wnan.119
- The paper
- Plummer, E. M., & Manchester, M. (2011). Viral nanoparticles and virus‐like particles: platforms for contemporary vaccine design. WIREs Nanomedicine and Nanobiotechnology. https://doi.org/10.1002/wnan.119
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
